Introduction
============

*Candida* species, opportunistic pathogens, are a major cause of morbidity and mortality worldwide and thus represents a serious threat to public health ([@B181]; [@B132]; [@B167]). Further, *Candida* species can cause vaginitis, oral candidiasis, cutaneous candidiasis, candidemia, and systemic infections ([@B261]). Candidemia is the most frequent hospital infection accounting for up to 15% of bloodstream infections, and *Candida* species are the main causative agents in 50--70% of systemic fungal infections ([@B44]; [@B117]; [@B12]).

*Candida albicans* is the pathogenic species most frequently isolated. However, other species such as *C. glabrata, C. tropicalis*, *C. parapsilosis*, *C. krusei*, *C. famata, C. guilliermondii*, and *C. lusitaniae* have been increasingly isolated, mainly in human immunodeficiency virus (HIV)-infected individuals ([@B24]; [@B66]; [@B134]; [@B171]; [@B12]).

The pathogenesis of *Candida* species is poorly understood, and the rate of infections is increasing rapidly. Further, a steady increment in resistance to traditional antifungal has resulted in the need to control *Candida* infections through early diagnosis and prevention of candidiasis.

Among the available antifungal agents, azoles are the preferred and most frequently used drugs for treatment of *Candida* infections. Depending on the type of infection, the anatomical site in which it occurs and the sensitivity profile of species, other antifungals can also be used. Among these, there are polyenes, echinocandins, nucleoside analogs and allylamines ([@B182], [@B185]; [@B167]). Fluconazole (FLZ), a type of azole, is often preferred in treatments of *Candida* infections because of its low cost and toxicity, in addition to availability in varied formulations ([@B183]). However, there are many reports in the literature on the development of resistance among *Candida* species, especially in relation to azoles, which is essential for the determination of resistance mechanisms presented by fungi with the objective of developing new classes of antifungal for treatment of *Candida* infections.

The need of the hour includes the development of a more effective therapy, since the phenomenon of resistance caused the appearance of new fungal infections, in addition to facilitating the resurgence of the existing ones. In this way, the control of *Candida* infections is a challenge in the modern clinic. The design of new drugs from the traditional ones used in the clinic and the identification of new molecules with antifungal potential for the manufacture of new drugs, more effective and less toxic, are fundamental to face the challenge.

The present review examines infections caused by *Candida* species and describes our current understanding of the molecular basis of resistance development in these fungal species. In addition, this review describes some of the promising alternative molecules and/or substances that are effective pharmaceuticals for treating fungal infections and could be used as anticandidal agents, as well as their mechanisms of action.

Candida Infections
==================

Fungal infections are considered a serious health problem, especially in people with some impairment in the immune system and are a main cause of morbidity and mortality worldwide ([@B254]). In the last two decades, fungal infections have shown a significant increment. This high incidence has been related to factors such as the increase in the number of patients with compromised immune system, ([@B161]; [@B97]; [@B115]; [@B244]), the increasing number of patients receiving hyperalimentation through catheters or probes and use of broad-spectrum antibiotics ([@B22]). The rising number of patients requiring organ transplantations, as well as those with leukemia and diabetes also contributes to this phenomenon ([@B194]).

The most frequent fungal disease affecting populations in the world is candidiasis ([@B112]; [@B66]; [@B110]; [@B134]; [@B249]; [@B257]). There are several types of candidiasis as mucosal candidiasis, cutaneous candidiasis, onychomycosis and systemic candidiasis ([@B26]; [@B102]; [@B261]). An important fact is that candidiasis is an infection that can affect both immunocompromised and healthy people ([@B114]; [@B191]). Candidemia is another infection due *Candida* spp. and is the most relevant and prevalent nosocomial fungal infection associated with a high mortality rate (up to 49%) in patients with a compromised immune system ([@B184]; [@B213]). The association of *Candida* with bloodstream infections depends on patient's condition, age, and geographic region. Candidemia is such an important infection that in 10--40% of cases it is associated with sepsis or septic shock while *Candida* species as main agent of sepsis or septic shock are responsible for no more than 5% of the total number of cases ([@B85]).

Many species recovered from human samples have been identified as belonging to the genus *Candida* that almost half has implicated in serious infections. *C. albicans* continues to be the most prevalent species, representing the majority of isolates of fungal infections ([@B57]; [@B92]; [@B97]; [@B115]; [@B244]). However, the prevalence of other *Candida* species has increase substantially. These species are *C. parapsilosis, C. tropicalis*, *C. krusei*, *C. glabrata*, *C. guilliermondii*, *C. orthopsilosis, C. metapsilosis, C. famata*, and *C. lusitaniae* ([@B211]; [@B115]; [@B101]).

*Candida albicans* is a species that presents high degree of flexibility, being able to grow in extremely different environments regarding to the availability of nutrients, temperature variation, pH, osmolarity, and amount of available oxygen ([@B168]). This fact associated with the high resistance capacity of the species to antifungals, their virulent features, capability of forming biofilms with other species ([@B5]; [@B231]) make the genus *Candida* a serious risk to human health ([@B235]). Thus, *Candida* species are highly adaptable and possess numerous strategies to survive favors that might affect their overgrowth and change their susceptibility profiles.

In addition, it is difficult to identify specific *Candida* species, which may delay the use of precise therapeutics. For instance, microbiological tests using specific culture media do not differentiate many species of *Candida*. Often, it takes several days to obtain antifungal susceptibility information for *Candida* species ([@B42]). Although there are newer molecular techniques available for rapid yeast detection, such as fluorescence *in situ* hybridization (PNA-FISH), commercially available equipment for analysis does not differentiate between *C. albicans* and *C. parapsilosis*, *C. glabrata*, or *C. krusei*. These facts are relevant because increased mortality rate is associated with delays in initiating adequate antifungal therapy ([@B71]; [@B15]).

Traditional Agents and Mechanisms of Action
===========================================

Fungal cells, like human cells, are eukaryotic; both cell types are targeted by antifungal compounds, resulting in considerable side effects in patients and fewer available targets for drug action. Since the 1990s, there has been an increasing, but limited, discovery of antifungal agents ([@B213]; [@B168]). These drugs include azoles, that inhibit ergosterol biosynthesis \[FLZ, itraconazole (ITC), ketoconazole (KTC), miconazole and clotrimazole\]; polyenes \[amphotericin B (AMB) and nystatin\]; allylamines; thiocarbamates; morpholines; 5-fluorocytosine, a deoxyribonucleic acid (DNA) analog; and echinocandins (for instance, caspofungins) ([@B166]; [@B239]). Three cellular components of fungi are targeted by these drugs. In endoplasmic reticulum of the fungal cell, azoles inhibit ergosterol biosynthesis by interfering with the enzyme lanosterol 14-α-demethylase, involved in the transformation of lanosterol into ergosterol, component that is part of the plasma membrane structure of the fungus (**Figure [1](#F1){ref-type="fig"}**). Thus, accumulation of 14-α-methyl-3, 6-diol, a toxic compound, will occur. As the concentration of ergosterol is reduced, the cell membrane structure is altered, thereby inhibiting fungal growth ([@B209]).

![Mechanisms of action of traditional antifungal agents on cellular targets. Azoles inhibit the ergosterol synthesis in the endoplasmic reticulum of the fungal cell. They act by interfering with the enzyme lanosterol 14-α-demethylase, involved in the transformation of lanosterol into ergosterol. Polyenes act in the fungal membrane by binding to ergosterol and causing disruption of the membrane structure promoting extravasation of intracellular constituents and, consequently, cell death. Flucytosine inhibits the thymidylate-synthetase enzyme interfering with DNA. Echinocandins inhibit (1,3) β-[D]{.smallcaps}-glucan synthase, thereby preventing glucan synthesis, which is present in the cell membrane of fungi. Allylamines and thiocarbamates inhibit the enzyme squalene-epoxidase, which participates in the synthesis of ergosterol. Griseofulvin acts by disrupting spindle and cytoplasmic microtubule production, thereby, inhibiting fungal mitosis.](fmicb-09-01351-g001){#F1}

Azoles comprise a 5-member azole ring containing two (imidazole) or three nitrogen atoms (triazole) attached to a complex side chain ([@B74]; [@B80]). The azole family of compounds includes the imidazoles (KTC, miconazole, econazole and clotrimazole) and triazoles (FLZ, ITC, and voriconazole, which is a synthetic triazole derivative of FLZ of second-generation), and posaconazole (hydroxylated analog of itraconazole) ([@B104]; [@B133]). Ergosterol is similar to cholesterol present in plasma membrane of animal cells; however, most antimycotic agents that target ergosterol binding or synthesis do not cross-react with host cells because of sufficient structural differences between these molecules ([@B239]).

Amphotericin B and others polyenes act in fungal membrane by binding to ergosterol and causing disruption of the membrane structure, which promotes extravasation of intracellular constituents such as potassium, magnesium, and sugars and, consequently, cell death ([@B178]; [@B137]; **Figure [1](#F1){ref-type="fig"}**).

Flucytosine (5-FC) is a pyrimidine analog with fungistatic properties that enters the fungal cell through cytosine permease and inhibits the thymidylate-synthetase enzyme interfering with DNA. 5-FC can also be converted to 5-fluorouracil which in turn can be phosphorylated to 5-fluorodeoxyuridine monophosphate. This one being also phosphorylated can be incorporated into RNA molecules, thus interfering with the cell translation process ([@B50]; [@B239]; [@B133]; **Figure [1](#F1){ref-type="fig"}**). Further, 5-fluorodeoxyuridine is associated with considerable toxicity ([@B171]). Clinical use of 5-FC is preferred in association with AMB ([@B204]; [@B154]; [@B189]), since the use of 5-FC alone induces stronger side-effects, such as hepatic impairment, interference with bone marrow function, and rapid occurrence of resistance especially among *Candida* species ([@B81]; [@B154]; [@B189]).

According to the type of infection and the sensitivity/resistance profile of the isolates, as well as the site of origin of the samples all antifungal agents may be used with varying efficiency ([@B182]). AMB is considered the gold standard drug for most mycoses that affect patients at risk ([@B137]). However, AMB has high toxicity, which limits its use. Nephrotoxicity is a main effect resulting from AMB administration ([@B137]; [@B154]). To minimize this problem and to increase the effectiveness of treatment, some formulations have been developed. Liposomal AMB (Ambisome^®^) allows for lower absorption of AMB by the reticuloendothelial system, which results in greater permanence in the bloodstream. A lipid complex of AMB (Abelcet^®^) comprises 50% AMB and 50% lipid compound and AMB in a colloidal dispersion (Amphocil^®^/Amphotech^®^, formed by a stable complex with cholesterol sulfate). However, the high cost of these formulations has limited their use ([@B104]; [@B137]; [@B168]; [@B154]).

Azoles represent the class of antifungals with the highest number of drugs. Azoles have fungistatic properties that affect cell growth and proliferation; a large amount of accumulated toxic sterols can eventually lead to fungal cell death ([@B225]; [@B189]). Such agents are preferred in the treatment of candidemia ([@B239]; [@B133]) and candidiasis. Among azoles, miconazole and KTC (imidazoles) first emerged and were the only drugs available for systemic use, with KTC being the first alternative to AMB ([@B81]; [@B222]). Then triazoles as itraconazole and FLZ have emerged, more effective and better tolerated than KTC ([@B58]).

Fluconazole is the drug of choice for most *Candida* infections ([@B183]; [@B171]) and is the most recommended antifungal agent, attributable to its low cost, for use in invasive candidiasis in patients who have not previously been medicated with azole antifungal agents ([@B231]; [@B168]).

Azole antifungals have limitations to their use, although they are generally well-tolerated. Limitations include adverse effects such as hepatotoxicity and the emergence of resistance among fungal isolates ([@B28]). Azoles can be toxic because they act as substrates or inhibitors of several enzymes such as cytochrome P450 enzymes. Further, these limitations provide motivation for improving this class of antifungal agents ([@B154]).

Alterations in triazole molecule gave rise to voriconazole (structurally related to FLZ) and posaconazole (related to ITC), a second generation of antifungals. Both are available for systemic therapy and have been shown to have better specificity and antifungal potency than that of first generation triazoles ([@B154]).

A new class of drugs, the echinocandins, has been shown to have fungicidal effects in all *Candida* species ([@B154]). The echinocandins include caspofungin, micafungin, and anidulafungin ([@B82]; [@B103]; [@B168]). Echinocandins inhibit (1,3) β-[D]{.smallcaps}-glucan synthase, thereby preventing glucan synthesis, which is present in the cell membrane of fungi (**Figure [1](#F1){ref-type="fig"}**). β-[D]{.smallcaps}-Glucan synthase inhibition depletes glucan polymers in fungal cells, resulting in an abnormal cell wall that is weak and unable to resist osmotic stress ([@B39]; [@B109]). This class of drugs has certain advantages attributable to its effects on the fungal cell wall, including a lower risk of side effects since animal cells do not have this structure. Further, echinocandins can be used in cases of azole-antifungal resistance ([@B239]; [@B82]; [@B133]; [@B168]).

Allylamines (terbinafine and naftifine) and thiocarbamates inhibit the enzyme squalene-epoxidase, which participates in the synthesis of ergosterol and is encoded by the *ERG1* gene (**Figure [1](#F1){ref-type="fig"}**). Inhibition of squalene-epoxidase leads to membrane rupture and accumulation of squalene. Allylamines effects can also prevent the production of other sterol derivatives.

Another antifungal is the tricyclic spirodiketone griseofulvin that acts by interfering the cytoplasmic microtubule production, disrupting spindle formation and, thereby inhibiting fungal mitosis (**Figure [1](#F1){ref-type="fig"}**). Griseofulvin was isolated from *Penicillium griseofulvum*, ([@B69]).

Certain pharmacological strategies have been developed to minimize toxicity and resistance. Development and use of new antifungal formulas (liposomal AMB, AMB lipid complexes, AMB colloidal dispersions, and AMB lipid nanosphere formulations), itraconazole, and β-cyclodextrin itraconazole is one strategy. Others include combination therapies of antifungal compounds (for example, AMB + 5-FC, FLZ + 5-FC, AMB + FLZ, caspofungin + liposomal AMB, and caspofungin + FLZ) (**Table [1](#T1){ref-type="table"}**) and nanostructuring of conventional antifungal agents ([@B6]; [@B239]; [@B240]; [@B238]).

###### 

Various regimes of combinatorial antifungal therapy showing better efficacy in combination than that of independent drugs.

  -----------------------------------------------------------------------------
  Combination of antifungals   Target                        Reference
  ---------------------------- ----------------------------- ------------------
  AMP B + Posaconazole\        *Candida* biofilms            [@B19]; [@B198].
  AMP B + Caspofungin                                        

  Micafungin + Fluconazole\    *Candida* infections          [@B220];\
  Micafungin + Voriconazole\                                 [@B64].
  Micafungin + AMP B                                         

  Flucytosine + Voriconazole   *Candida* infections          [@B19]

  Minocycline + Fluconazole    *Candida albicans* biofilms   [@B19]

  Posaconazole + Caspofungin   *Candida* infections          [@B36]; [@B41]

  Terbinafine + Azole          *Candida* growth              [@B11]; [@B172]

  Echinocandin + Azole         Invasive candidiasis          [@B51]

  AMP B + Flucytosine          Invasive candidiasis          [@B167]
  -----------------------------------------------------------------------------

AMP B, amphotericin B.

[@B36] evaluated the sensitivity profile of reference and clinical samples of *C. albicans*, *C. glabrata*, and *C. parapsilosis* in relation to antifungals like azoles and equinocandinas. They found that despites clinical isolates had relatively high azole and echinocandin MICs, some synergistic combinations were found for AMB- posaconazole against *C. glabrata* and AMB- anidulafungin and AMB- caspofungin against *C. parapsilosis* by both visual and spectrophotometric readings. [@B41] a potential therapeutic applicability for posaconazole and caspofungin combinations in the future. Their studies reported that posaconazole exhibits *in vitro* and *in vivo* synergy with caspofungin against drug susceptible or resistant *C. albicans* strains (derived echinocandin-resistant mutants).

[@B167] drew attention to the fact that a combination of liposomal AmB, 5 mg/kg daily, and flucytosine, 25 mg/kg 4 times daily, may be considered as salvage therapy in patients who have not had a clinical response to initial AmB therapy in cases of central nervous system infections by fungus in neonates.

Examples of some others publications on combination therapy between different antifungal drugs are shown in **Table [1](#T1){ref-type="table"}**.

However, among traditional antimycotic drugs, none has all the qualities required for an ideal agent ([@B265]). All drugs have at least one of the following restrictions: they do not have a broad spectrum of action, some are fungistatic, and others have high toxicity and low bioavailability with significant side effects in patients undergoing therapeutic regimens ([@B179]; [@B200]; [@B112]; [@B259]; [@B17]). Therefore, limitations of treatment and drug resistance ([@B27]; [@B179]; [@B150]; [@B252]) associated with pathogenicity of the clinical isolates support the urgent need to identify substances that are more effective, with new mechanisms of action in the fight against *Candida* infections.

Mechanisms of Cellular and Molecular Antifungal Resistance
==========================================================

There are three types of antifungal resistance, including a primary or intrinsic form that exists prior to antifungal exposure. The second type is an acquired form that occurs after antifungal exposure and may be reversible, attributable to transient or non-reversible adaptation resulting from several genetic alterations. A clinical form refers to unfavorable outcomes in patients despite antifungal therapy and is directly linked to primary or secondary resistance ([@B49]).

Populations are increasingly at risk of fungal infections, resulting in an increased use of antifungal agents. Consequently, higher minimum inhibitory concentrations (MIC) for antifungals against *C. albicans* strains have been observed and may be related to therapeutic failures. In addition, some non-*albicans Candida* (NAC) species have inherent resistance to azoles ([@B163]; [@B121]; [@B68]). Low-dose prophylactic administration of azole derivatives, such as FLZ, for prolonged periods to prevent the occurrence of opportunistic infections in immunosuppressed patients also results in resistant phenotypes ([@B233]; [@B193]). These facts are likely to collaborate to the increased incidence of fungal infections. Resistance to polyenes (AMB) in *C. albicans* is less common and is associated with the substitution of ergosterol with a precursor molecule or a general reduction of sterols in the plasma membrane ([@B98]) (**Figure [2](#F2){ref-type="fig"}**). Enzymes such as Δ~5,6~-desaturase, encoded by *ERG3* gene, and C-8 sterol isomerase, encoded by *ERG2* gene participate in ergosterol biosynthesis and have the main alterations related to AMB resistance. These enzymes influence the amount of ergosterol required for the action of polyenes because the mutations are responsible for modifications in sterol content ([@B229]). For instance, Δ~5,6~-desaturase when mutated converts fecosterol to episterol which has low affinity for AMB. Another likely AMB-resistant mechanism is the reduction of oxidative damage via enhanced catalase activity ([@B98]).

![Different mechanisms of multidrug resistance adopted by fungal cells. The main mechanisms of drug resistance against azoles, polyenes, echinocandins, and flucytosine include: (a) alteration of the enzyme target (genes encoding ergosterol biosynthetic pathway enzymes -- AZOLES, glucan synthases -- ECHINOCANDINS, cytosine deaminase or uracil phosphoribosyltransferase -- FLUCYTOSINE) leading to poor binding of toxic drugs to its enzyme target sites, (b) overexpression of drug efflux proteins leading to increased efflux -- AZOLES, (c) changes in membrane property/composition affecting normal drug import -- FLUCYTOSINE, (d) Reduction of sterols in plasma membrane -- POLYENES. Colored balls mean antifungal molecules.](fmicb-09-01351-g002){#F2}

Possible mechanisms for cellular and molecular resistance to FLZ in *C. albicans* are described. The first is related to induction of multi-drug pumps, which decrease the concentration of drug available for the target enzyme, 14-α-demethylase, in fungal cells ([@B98]) (**Figure [2](#F2){ref-type="fig"}**). There are two types of active transporters in *C. albicans*, including those encoded by the *Candida* drug resistance*-CDR* genes (Cdr1 and Cdr2) and those encoded by the multidrug resistance*-MDR1* genes. Cdr1- and Cdr2-type pumps are ATP-binding cassette (ABC) transporters, and Mdr1 is a major facilitator superfamily (MFS)-type pump that transports solutes from different sides of the fungal cell plasma membrane. Overexpression of transporters encoded by *CDR* genes confers cross-resistance to various azole-derived compounds, while overexpression of those transporters encoded by *MDR1* genes is responsible for FLZ resistance. Superexpression of these transporters prevents accumulation of the drug in the intracellular compartment ([@B98]; [@B180]) (**Figure [2](#F2){ref-type="fig"}**).

A second mechanism of resistance involves modification of the target enzyme encoded by the *ERG11* gene, also known as cytochrome P~450~ lanosterol 14 α-demethylase (Cyp51) (**Figure [2](#F2){ref-type="fig"}**). Mutations in this gene prevent azoles from binding to enzyme sites ([@B126]; [@B67]). Another mechanism of resistance to azoles is related to substitution of ergosterol by another sterol. Mutations in the *ERG3* gene does not convert 14-α-methylfecosterol into 14-α-methyl-3,6-diol. This substitution causes azoles to have no fungistatic effects on the fungal cell membrane ([@B209]).

Two possible mechanisms of resistance to echinocandins have been reported. The first deals with point mutations in gene that encodes the major subunit of the glucan synthase enzyme (Fks subunit) (**Figure [2](#F2){ref-type="fig"}**). These mutations occur only in two regions of the gene (known as "hot-spot"), are dominants and can provide resistance to all echinocandin ([@B177]). The consequence is that these mutations lead to the production of high MIC values. For instance, *C. parapsilosis* and *C. guilliermondii* present MIC values 4- to 100-fold greater compared to those observed for *C. albicans.* The *FKS1* mechanism extends to other NAC species such as *C. tropicalis*, *C. parapsilosis*, *C. glabrata*, *C. krusei*, *C. guilliermondii*, and *C. dubliniensis* that show the same mutations as those of *C. albicans* ([@B99]; [@B176]). In that way, *FKS1*-mediated resistance mechanisms can be pervasive in the fungal kingdom because it is suggested that it can be responsible for a reduced inherit sensitivity of certain *Candida* species and molds ([@B175]).

The second mechanism of resistance involves the response to adaptation stress. When there is an inhibition of production of fungal cell wall component, microorganism is capable of increasing the production of another one. Some research showed that many *Candida* species respond to the inhibition of Fks synthesis producing high amounts of chitin ([@B32]; [@B230]). [@B32], studying *Candida* bloodstream isolates from cancer patients, observed a process known as the paradoxical effect in some isolates of *Candida*, that is, isolates are capable of growing in the presence of high concentrations of echinocandins (above the MIC). This phenomenon was strikingly absent in *C. glabrata* isolates, but was well evidenced in *C. parapsilosis*, *C. tropicalis*, and *C. krusei* ones ([@B32]).

Resistance to 5-FC can be of two types: primary, occurring via cytosine permease (encoded by the *FCY2* gene) with decreased drug uptake ([@B208]) (**Figure [2](#F2){ref-type="fig"}**); secondary, related to alterations in cytosine deaminase (encoded by *FCY1*) or uracil phosphoribosyltransferase (encoded by *FUR1*) enzymes activities. Cytosine permease is responsible by conversion of 5-FC to 5-fluorouridine or to 5-fluorouridine monophosphate (5-FUMP) ([@B105]; [@B63]) Resistance is easily developed in fungal isolates from patients who are receiving the drug. However, most of these mechanisms have only been observed in others species of *Candida*, but not in *C. albicans* ([@B165]). Therefore, other molecular mechanisms related to resistance to 5-CF must exist, playing relevant role in fungal resistance ([@B216]).

[@B46] recently reported a relation between arginine metabolic enzymes and 5-FC resistance, suggesting that 5-FC resistance requires somehow high arginine production. Accordingly, [L]{.smallcaps}-arginine concentrations in some body fluids in healthy individuals, as vaginal fluid ([@B79]) or human plasma ([@B7]) can be as high as 0.1 mM. The molecular mechanisms involved in arginine and 5-FC resistance relationship have not been clarified, but the results obtained by the authors highlight the significance of a new possibility of fighting resistance to 5-FC.

Mutations in Genes Associated With Resistance to Azoles in *Candida* Species
----------------------------------------------------------------------------

Studies aimed at elucidating the molecular mechanisms responsible for developing resistance to *Candida* species have predominantly focused on resistance to azoles, as they are the most commonly used drugs clinically ([@B31]; [@B84]). Thus, the main research targets include the *CDR1*, *CDR2*, and *MDR1* genes ([@B190]; [@B269]; [@B149]; [@B251]). In addition, mutations in transcription factors associated with the *CDR1* and *CDR2* genes ([@B37]; [@B47]; [@B263]), specific mutations or superexpression of *ERG11* genes, and mutations in the *ERG5* or *ERG3* genes (also involved in ergosterol biosynthesis), have been identified. Most of them were related to FLZ resistance ([@B207]; [@B118]; [@B128]).

Mutations Associated With Efflux Pump Genes (*CDR1*, *CDR2*, and *MDR1*) and Transcription Factors
--------------------------------------------------------------------------------------------------

An important and potent mechanism of multi-drug resistance (MDR) in fungi is the intracellular accumulation of antifungals by increased efflux of drugs ([@B187]; [@B188]). In *C. albicans*, overexpression of genes encoding transporters proteins, mainly *CDR1* and *CDR2* genes (encoding Cdr1 and Cdr2, respectively, which are ABC multidrug transporter proteins) or *MDR1* gene (encoding the MFS efflux pump protein Mdr1) is considered the main mechanism responsible for antimycotic resistance in *Candida* isolates ([@B70]; [@B120]; [@B125]; [@B264]; [@B108]; [@B157]; [@B187]; [@B188]). Increased production of the Cdr1 transporter is responsible for FLZ, KTC, and ITC resistance. In contrast, expression of the *Candida* drug resistance protein 2 (Cdr2p) is related to FLZ and ketoconazole resistance, but does not affect resistance to itraconazole ([@B251]). There are related multidrug transporters with MDR function in NAC species such as those in *C. glabrata* (CgCdr1, CgCdr2 and Snq2) ([@B139]; [@B206]; [@B248]) and in *C. krusei* (*ABC1)* ([@B100]).

Azole resistance in *C. glabrata* probably is also related to upregulation of homologous transporter genes *CgCDR1* and *CgCDR2* ([@B206], [@B205]; [@B18]), and genetic evidence has been provided that supports a role for multidrug transporters in azole resistance in *C. glabrata* ([@B206]).

[@B119] investigated expression of the *C. albicans* and *C. glabrata CDR1* and *MDR1* genes associated with azole resistance in patients with vaginitis. There was overexpression of genes to varying extents in all *Candida* isolates tested and this result was correlated with the degree of resistance, as evidenced by antifungals MICs. The authors also observed that in one *C. albicans* resistant isolate there was overexpression of messenger RNA for Mdr1 after superexpression of Cdr1, which suggests a synergism between these drug efflux pumps proteins. DNA sequence analysis of the *CDR1* promoter region also suggests there are several point mutations in resistant clinical isolates that are not present in susceptible isolates. Thus, this region is important for binding of transcription factors and for increasing the affinity of activators responsible by *CDR1* expression in drug resistant isolates.

[@B210] evaluated the molecular mechanisms of resistance in 29 nosocomial isolates of *C. glabrata* recovered during 3 years of study; of these, most were resistant to FLZ. Quantitative real-time PCR analyses provided evidence that azole resistance in these isolates probably was due the upregulation of genes *CgCDR1*, *CgCDR2*, and *CgSNQ2*, encoding efflux proteins in *C. glabrata*.

[@B100] identified two homologous ABC transporter genes (*ABC1* and *ABC2*) in *C. krusei* previously described for *C. albicans*. When cultures of *C. krusei* were exposed to imidazole and cycloheximide, *ABC1* gene was upregulated. [@B111] showed that *ABC1* is involved in the inherent resistance of *C. krusei* to azoles. In *C. parapsilosis* authors have shown that *MRR1* is involved in resistance to FLZ ([@B237]; [@B270]); however, in *C. tropicalis*, efflux pumps genes related to azoles resistance have not yet been identified ([@B13]).

[@B76] also studied the expression of *CDR1*, *CDR2*, and *MDR1* genes in 120 strains of *C. albicans* (60 resistant and 60 azole susceptible) obtained from clinical samples and observed that the expression of Cdr1, Cdr2, and Mdr1 was higher in azole-resistant strains than that in sensitive strains. Several transcription factors have been identified as responsible for upregulating *CDR1*, *CDR2*, and *MDR1* genes, with several serving as positive *MDR1* regulators ([@B48]; [@B263]) and others as negative *MDR1* regulators ([@B38]).

Overexpression of the *CDR1* and *CDR2* genes has been suggested to influence the relationship between susceptibility and resistance to azoles and AMB. According to [@B196], azole-resistant strains of *C. albicans* that overexpress *CDR1* and *CDR2* are hypersensitive to AMB. In contrast, knockout strains for the *CDR1* and *CDR2* genes are resistant to AMB, suggesting that the ergosterol content determines sensitivity to both azoles and AMB in *C. albicans*, and that there is an inverse susceptibility to these drugs that is directly associated with Cdr1 and Cdr2 transporters. The authors also suggest a new therapeutic approach for administering alanine phosphoricin B in situations of fungal resistance to azoles rather than increasing the administered dose of the azole agent.

Major facilitator superfamily (MFS) transporters were first identified in *C. albicans* and are the second major superfamily of transporters also related to drug efflux in this species ([@B201]; [@B72]). MFS proteins consist of one polypeptide chain two three-dimensional regions with independent functions ("domains") having six transmembrane alpha helical spanners (TMSs). There are two types of MFS proteins, including DHA1 (drug:HC antiporter-1) with 12 TMSs, and DHA2, which has 14 TMSs. The main multidrug protein of *C. albicans* is MDR1 from the DHA1 subfamily. Homologs of *CaMDR1* were identified in *C. glabrata* (*CgMDR1*) and in *C. dubliniensis* (*CdMDR1*). *CgMDR1* is constitutively expressed and confers specific resistance to FLZ in *C. glabrata*; therefore, this phenomenon could explain the intrinsic resistance of this yeast to triazoles ([@B145]; [@B206]). In *C. dubliniensis* overexpression of *CdMDR1* is considered a main mechanism of FLZ resistance in isolates of this species ([@B145]).

Mutations Associated With the *ERG11* Gene
------------------------------------------

In *C. albicans*, a 1587 bp gene encodes Erg11 protein. Erg11 has 595 amino acids. Up to now, approximately more than a hundred non-synonymous point mutations have been identified in clinically resistant isolates ([@B158]; [@B241]). Interestingly, most of these substitutions occur in 3 regions ranging from 105 to 165, 266 to 287, and 405 to 488 amino acids ("hot spots") instead of being randomly dispersed ([@B126]; [@B262]). However, many of the identified mutations are not resistant and are considered genetic polymorphisms occurring in living organisms. Few of these mutations have been demonstrated to support azole resistance ([@B158]; [@B241]). *ERG11* genetic polymorphisms should be considered in the rational design of novel azole-derived drugs, attributable to certain polymorphisms identified in the gene that do not necessarily characterize changes in the amino acids and three-dimensional structure of proteins, and therefore, do not reduce the affinity between azolic components and the protein. Thus, mapping all *ERG11* amino acid changes involved in azole resistance could help in the design of new azole antifungals with potent activity against resistant strains.

Recent studies corroborate these facts. For instance, [@B148] investigated the susceptibility of FLZ, ITC and voriconazole in isolates of *C. albicans* and verified 23 distinct substitutions, 2 of which were suspected as being involved in azole resistance. [@B76] verified 19 changes in the *ERG11* gene sequence and found that five alterations occurred in azole resistant strains only (A530C, G622A, G1309A, A1167G, and A1230G). Further, 33% of azole-resistant strains were characterized by the simultaneous presence of the A530C, G622A, and A1167G mutations. [@B25] identified 21 specific mutations in the *ERG11* gene, two of which were significantly associated with drug resistance, including a nucleotide substitution at position 798, which was related to an increase in drug resistance, and a silence mutation at position 1440, which significantly decreased the chance of a strain being resistant to drugs.

*ERG11* mutations conferring azole resistance in *C. tropicalis* ([@B256]; [@B96]), *C. krusei* ([@B197]), *C. dubliniensis* ([@B173]), and *C. parapsilosis* ([@B83]) clinical isolates have also been described; however, there is no relate about these mutations in *C. glabrata* ([@B78]).

In addition to mutations that directly affect the *ERG11* gene, there are changes in transcription factors associated with this gene that may also affect its expression and, consequently, the biosynthesis pathway of ergosterol. The *C. albicans* Upc2p transcription factor (*CAUPC2*) gene is among the regulators of *ERG11* gene expression.

Overexpression of *ERG11*
-------------------------

It is known from the literature that overexpression of *ERG11* gene, or maybe its upregulation, are responsible for the resistance to azole agents. Accordingly, different methods have been used to measure the level of *ERG11* expression by detecting and quantifying its mRNA. A 3- to 20-fold increase in mRNA production was observed in resistant strains ([@B209]).

Two independent mechanisms have been shown to drive *ERG11* overexpression. One is related to a chromosomal mutation (duplication) of *ERG11* gene. This phenomenon was demonstrated first in *C. glabrata* isolates ([@B127]); this occurs when an isochromosome is formed in the region having the *ERG11* gene. In that way, this specific region will now have two copies of the left arm of chromosome 5, duplicating the chromosome ([@B218]). The second depends on a transcription factor that regulates the ergosterol biosynthesis (Upc2p, coded by the *CaUPC2* gene) identified in *C. albicans*. Upc2p recognizes and is specifically bound to the promoters (the well-known SRE box, of sterol response element) of different *ERG* genes that activate gene transcription ([@B158]).

Antifungal drugs, including FLZ, induce the expression of *CaUPC2* gene, and the Upc2p transcription factor upregulates *ERG2* and *ERG11* gene expression when *C. albicans* is grown under azole drug pressure ([@B4]). Studies have shown that strains that have undergone homozygous deletion of the *CaUPC2* gene are hypersensitive to several drugs and accumulate significantly less cholesterol, suggesting a decrease in ergosterol in these strains ([@B234]).

Different strains of *C. albicans* and probably other *Candida* species express different *UPC2* alleles encoding for transcription factors of different strength. In addition, three gain of function mutations (A643T, A643V, and G648D) have been characterized in sequential clinical isolates overexpressing *ERG11*. Upc2 proteins act constitutively and lead to loss of sensitivity to azoles ([@B158]).

Alternative Agents as Anticandidal Agents
=========================================

Increased drug resistance in fungi is a problem that cannot be avoided, particularly for FLZ, which is the preferred antifungal for treating candidiasis in acquired immunodeficiency syndrome (AIDS) patients ([@B233]; [@B193]). Moreover, there are fungi that have intrinsic resistant to antifungal agents commonly used in the clinic ([@B272]). In addition, biofilms, an ordinary virulence property of fungi, has as main characteristic the capacity of resistance to drugs ([@B34]; [@B219]).

Peptides as Antifungal Agents
=============================

Some peptides isolate from various sources of body have antimicrobial properties and are also a promise in the discovery of new antimycotics. One possibility is to use molecules with antifungal properties derived from host cells to prevent or treat fungal infections (**Table [2](#T2){ref-type="table"}**). There are some small cationic peptides derived from large proteins that exert antifungal activities (**Table [3](#T3){ref-type="table"}**). The main mechanism of action related to these peptides is that they intensify the passage of substances through the fungal membrane favoring permeabilization. These peptides include lysozyme, lactoferrin, defensins, histatin, and cathelicidins ([@B136]) (**Figure [3](#F3){ref-type="fig"}**).

###### 

Alternative products with reported antifungal activities against *Candida* species showing promise for antifungal drug development.

  Specific source                                                                                    Biological active molecules/substances                                                                              Activity/putative mechanisms of action
  -------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------
  New triazoles                                                                                      Ravuconazole                                                                                                        Inhibits ergosterol biosynthesis
                                                                                                     Albaconazole                                                                                                        Inhibits ergosterol biosynthesis
                                                                                                     Isavuconazole                                                                                                       Inhibits ergosterol biosynthesis
  Peptides                                                                                           Lysozyme                                                                                                            Reduces SAP activity and secretion
                                                                                                     Lactoferrin                                                                                                         Production of cationic antimicrobial peptide lactoferricin
                                                                                                     Defensins                                                                                                           Increases membrane permeability
                                                                                                     Histatin                                                                                                            Inhibition of adhesion
                                                                                                     Cathelicidins                                                                                                       Increases membrane permeability
  Plants (essential oils; terpenoids; saponins; phenolic compounds; alkaloids; peptides; proteins)   Curcumin                                                                                                            Inhibiting initial cell adhesion, biofilm growth, and gene expression
                                                                                                     *Eugenia dysenterica* (catechin derivatives and flavonoids)                                                         Inhibits planktonic growth
                                                                                                     *Terminalia catappa* (hydrolysable tannins (punicalin, punicalagin), gallic acid, and flavonoid C-glycosides)       Inhibits planktonic growth
                                                                                                     *Carya illinoensis* (gallic acid, ellagic acid, flavonoids -- rutin -- and tannins -- catechins and epicatechins)   Inhibits the production of germ tubes
                                                                                                     Quercetin, myricetin, kaempferol (flavanols)                                                                        Inhibits planktonic growth
                                                                                                     *Syzygium cordatum* (gallotannin)                                                                                   Inhibits planktonic growth
                                                                                                     *Scutellaria baicalensis* (baicalein)                                                                               Induces apoptosis in *Candida albicans*
                                                                                                     *Ocotea odorifera* (ellagitannins)                                                                                  Potent activity against *Candida parapsilosis*
                                                                                                     *Cymbopogon nardus* essential oil                                                                                   Inhibits hyphal growth in *C. albicans*
                                                                                                     *Artemisia judaica* essential oil                                                                                   Inhibits the formation of germination tube and biofilms in *C. albicans*
                                                                                                     Thymol (terpene)                                                                                                    Binds to ergosterol in the membrane resulting in cell death
                                                                                                     Carvacrol (terpene)                                                                                                 Alters cellular cytoplasmic membrane and induces apoptosis
                                                                                                     *Lannea welwitschii* (alkaloids, flavonoids, steroids, sapogenetic glycosides, tannins)                             Wound healing
                                                                                                     *Lonicera japonica* (chlorogenic acid)                                                                              Antiwound infection, repair, and contraction

SAP, secreted aspartic protease.

###### 

Predicted amino-acid sequences (single-letter code) of antimicrobial peptides obtained from Protein Data Bank (RCSB-PDB) or from literature reference.

  ---------------------------------------------------------------------------------------------------------------------------------------
  Peptide                              Origin   Amino-acid sequence                            Accession Number (UniProtKB)   Reference
  ------------------------------------ -------- ---------------------------------------------- ------------------------------ -----------
  LL-37                                Human    LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES          P49913                         [@B247]

  CRAMP                                Mouse    GLLRKGGEKIGEKLKKIGQKIKNFFQKLVPQPE              P51437                         [@B247]

  Lysozyme                             Human    MKALIVLGLVLLSVTVQGKVFERC\                      P61626                         [@B8]
                                                ELARTLKRLGMDGYRGISLANWM\                                                      
                                                CLAKWESGYNTRATNYNAGDRS\                                                       
                                                TDYGIFQINSRYWCNDGKTPGAV\                                                      
                                                NACHLSCSALLQDNIADAVACAKRV\                                                    
                                                VRDPQGIRAWVAWRNRCQNRDVRQYVQGCGV                                               

  Lactoferrin                          Human    MKLVFLVLLFLGALGLCLAGRRRSVQWCAVSQPEA\           P02788                         [@B88]
                                                TKCFQWQRNMRKVRGPPVSCIKRDSPIQCIQAIAE\                                          
                                                NRADAVTLDGGFIYEAGLAPYKLRPVAAEVYGTER\                                          
                                                QPRTHYYAVAVVKKGGSFQLNELQGLKSCHTGLRRT\                                         
                                                AGWNVPIGTLRPFLNWTGPPEPIEAAVARFFSASCV\                                         
                                                PGADKGQFPNLCRLCAGTGENKCAFSSQEPYFSY\                                           
                                                SGAFKCLRDGAGDVAFIRESTVFEDLSDEAERDEY\                                          
                                                ELLCPDNTRKPVDKFKDCHLARVPSHAVVARSVNG\                                          
                                                KEDAIWNLLRQAQEKFGKDKSPKFQLFGSPSGQK\                                           
                                                DLLFKDSAIGFSRVPPRIDSGLYLGSGYFTAIQNL\                                          
                                                RKSEEEVAARRARVVWCAVGEQELRKCNQWSGLSE\                                          
                                                GSVTCSSASTTEDCIALVLKGEADAMSLDGGYVYTA\                                         
                                                GKCGLVPVLAENYKSQQSSDPDPNCVDRPVEGYL\                                           
                                                AVAVVRRSDTSLTWNSVKGKKSCHTAVDRTAGWNI\                                          
                                                PMGLLFNQTGSCKFDEYFSQSCAPGSDPRSNLCA\                                           
                                                LCIGDEQGENKCVPNSNERYYGYTGAFRCLAENA\                                           
                                                GDVAFVKDVTVLQNTDGNNNEAWAKDLKLADFAL\                                           
                                                LCLDGKRKPVTEARSCHLAMAPNHAVVSRMDKVE\                                           
                                                RLKQVLLHQQAKFGRNGSDCPDKFCLFQSETKNL\                                           
                                                LFNDNTECLARLHGKTTYEKYLGPQYVAGITNLK\                                           
                                                KCSTSPLLEACEFLRK                                                              

  HDB-1                                Human    MRTSYLLLFTLCLLLSEMASGGNFLTGLGHRSDH\            P60022                         [@B93]
                                                YNCVSSGGQCLYSACPIFTKIQGTCYRGKAKCCK                                            

  HDB-2                                Human    MRVLYLLFSFLFIFLMPLPGVFGGIGDPVTCLKSGAI\         O15263                         [@B94]
                                                CHPVFCPRRYKQIGTCGLPGTKCCKKP                                                   

  HDB-3                                Human    MRIHYLLFALLFLFLVPVPGHGGIINTLQKYYCRVR\          P81534                         [@B214]
                                                GGRCAVLSCLPKEEQIGKCSTRGRKCCRRKK                                               

  Porcine cathelicidin peptide PR-39   Pig      RRRPRPPYLPRPRPPPFFPPRLPPRIPPGFPPRF PPRFP-NH2   P80054                         [@B247]

  Histatin-5                           Human    DSHAKRHHGYKRKFHEKHHSHRGY                       P15516                         [@B86]

  P318                                 Mouse    KIGEKLKKIAQKIKNFFAKLVAQPEQ                     --                             [@B23]

  HsLin06_18                           Plant    FAYGGAXHYQFPSVKXFXK                            --                             [@B43]

  HBD3-C15                             Human    GKCSTRGRKCCRRKK                                --                             [@B116]

                                                                                                                              
  ---------------------------------------------------------------------------------------------------------------------------------------

![Representative models of some antifungical peptides showing alpha-helical, beta-sheet, amphiphilic structural motifs that relate forms and functions. The three-dimensional structure models of peptides were predicted using the on-line server Iterative Threading ASSEmbly Refinement (I-TASSER, Yang Zhang Lab), University of Michigan (Ann Arbor, MI, United States), from their amino acid sequences.](fmicb-09-01351-g003){#F3}

Accordingly, the utmost relevance in the health care field is the development of more safe and effective antimycotic agents. Therefore, this topic aimed to address new substances and/or molecules with potential antifungal activity, their clinical relevance, and mechanisms of actions. Alternative therapies with some antifungal potential include the use of synthetic agents, polymeric materials, active molecules of natural products and peptides (**Table [2](#T2){ref-type="table"}**).

New Triazoles
-------------

New triazoles antifungals are being developed and are under investigation, due to the limited number and the lack of effective antifungal. These include ravuconazole, albaconazole, and isavuconazole (**Table [2](#T2){ref-type="table"}**). Preliminary studies have shown that these drugs have good pharmacokinetic profiles and low toxicity, as well as *in vitro* activity against *Candida* even in FLZ-resistant strains, with similar properties to those of FLZ and voriconazole.

Albaconazole, a broad-spectrum antifungal agent with excellent tolerability ([@B14]), has shown great activity against *Candida* spp., both *in vitro* and *in vivo* studies, with better properties than those of FLZ. In fact, a single dose of albaconazole at a concentration almost 4× lower than that of FLZ recommended for acute vaginal candidiase has better efficacy ([@B170]). In addition, albaconazole showed low toxicity when administered to volunteer patients ([@B75]). Most isolates of *C. albicans* and *C. glabrata* are susceptible to treatment with albaconazole ([@B169]).

Isavuconazole is a new, second-generation triazole that has also a broad-spectrum antifungal activity. *In vitro*, isavuconazole is more active than AMB, ITC, voriconazole, 5-FC, and FLZ (MIC~50~ = 0.004, 0.5, 0.008, 0.03, 0.125, and 8 μg/ml, respectively) and has lower MIC~50~ values than those of voriconazole in the majority of *Candida* species ([@B169]). Isavuconazole has demonstrated activity against candidemia and invasive candidiasis, with an action mechanism similar to that of other triazoles and with activity in triazole-resistant fungi ([@B258]).

Ravuconazole is structurally similar to isavuconazole and has demonstrated a good antimycotic action in FLZ resistant isolates. However, higher MIC values for ravuconazole have been reported for *Candida* isolates that display resistance to FLZ than those for susceptible isolates ([@B169]).

Lysozyme is an enzyme found in various fluids of the human body such as saliva and respiratory secretions (**Table [3](#T3){ref-type="table"}** and **Figure [3](#F3){ref-type="fig"}**). It is classically known for its ability to kill bacteria through its muramidase activity. Further, lysozyme is active against numerous clinical isolates of *Candida* species, as well as against *Aspergillus fumigatus* and *Penicillium* species ([@B164]). However, the antifungal mechanisms of action associated with lysozyme remain subject to speculation. It is likely that lysozyme acts by reducing secreted aspartic protease (SAP, involved in *Candida* virulence) activity and secretion in *C. albicans* ([@B266]); its fungicidal activity at high concentrations likely results from damage to the cell wall or plasma membrane, causing loss of osmotic equilibrium ([@B266]).

Human lactoferrin (hLF) is a peptide that binds to iron and has protease action (**Table [3](#T3){ref-type="table"}** and **Figure [3](#F3){ref-type="fig"}**). Lactoferrin is found in saliva and other secretions of human body. It has been found to be active against *C. albicans* and *C. krusei* ([@B202]). The mechanisms of action associated with lactoferrin are likely related to production of a cationic peptide that presents a broad antimicrobial activity ([@B160]). It was verified that a synthetic peptide comprising the first cationic domain of lactoferricin H (released by pepsinolysis of hLF), named hLF1-11 (**Table [3](#T3){ref-type="table"}**), possesses a high antifungal activity, ([@B124]), beyond contributing to the clearance of infections, by stimulating the production of macrophages and dendritic cells ([@B255]). The peptide hLF1-11 also inhibited *C*. *albicans* biofilm formation at early stages, interfering with biofilm cellular density and metabolic activity and to induce the down-regulation of biofilm and hyphal-associated genes ([@B147]).

Histatin-5 is a fragment of salivary protein histatin-3 comprising the N-terminal fragment with 24 amino acids (**Table [3](#T3){ref-type="table"}** and **Figure [3](#F3){ref-type="fig"}**). The peptide has strong fungicidal activity, being able to kill both yeast and filamentous forms of *Candida* spp. even at low concentrations (15--30 μM); histatin-5 can also exert its fungicidal activity by binding to a candidate 67 kDa protein and then interfering with non-lytic ATP efflux ([@B62]). Moreover, when histatin-5 is adsorpted to microtiter plate prior *C. albicans* biofilm formation (90 min, 24, 48, and 72 h) it is capable of reducting significantly *C. albicans* colonization interfering with biofilm formation. ([@B140]). These data corroborate to those previously obtained by [@B260], who demonstrated the inhibitory effect of histatin-5 when adhered to hydroxyapatite and polymethylmethacrylate (PMMA) surfaces on *C. albicans* colonization.

Human β-defensins (HBD) are small cationic peptides that belong to the defensins family. There are three types of human β-defensin with fungicidal activity toward *C. albicans* ([@B107]; [@B215]; [@B246]) that function via the same mechanism ([@B107]), including human β-defensin-1 (HBD-1), human β-defensin-2 (HBD-2), and human β-defensin-3 (HBD-3) (**Table [3](#T3){ref-type="table"}** and **Figure [3](#F3){ref-type="fig"}**).

Pro-inflammatory molecules such as interferon-γ, bacteria, or lipopolysaccharide can stimulate the expression of HBD-1 mRNA constitutively in endothelial tissues, by binding to toll-like receptors (TLR) ([@B60]). In addition, HBD-1 is important for control of early mucosal *Candida* infections and plays a critical role in HBD-2 expression ([@B246]). Cytokines, such as tumor necrosis factor, and also the contact with bacteria and fungi ([@B87]) and interleukin (IL)-1 ([@B236]) stimulate the expression of HBD-2 in epithelial tissue via TLR-2 ([@B91]). HBD-3 expression is induced via binding of TGFα (transforming growth factor alpha) to its receptor EGFR (epidermal growth factor receptor). HBD-3 can be found in keratinocytes and airway epithelial cells ([@B236]). Of the three HBDs, HBD-3 is fungicidal against *C. albicans*, showing a minimal fungicidal concentration (MFC) of 2.5 μM; HBD-2 has a poor activity against fungi, with a MFC of 8 μM ([@B107]). Also, HBD-3 elevates Xog1 activity, an exoglucanase of *C. albicans* cell wall, resulting in reduced adherence of the yeast ([@B35]). Studies have shown that at least one mechanism of action associated with HBD-1, 2, and 3 increases the membrane permeability of *C. albicans* ([@B107]).

Other small cationic peptides include the cathelicidins \[human LL-37, murine cathelicidin-related antimicrobial peptide (CRAMP), and porcine PR-39\], a group of antimicrobial skin peptides produced by mast cells and by mucosal and skin epithelial cells ([@B135]) (**Table [3](#T3){ref-type="table"}** and **Figure [3](#F3){ref-type="fig"}**). CRAMP is both fungicidal and fungistatic against *C. albicans*, with MICs as low as 15 μM. LL-37 also has fungicidal and fungistatic activity and can be cleaved into shorter peptides with a higher fungicidal activity against *C. albicans*. Assays have shown that LL-37 and RK-31 affect membrane permeability of *Candida* cells. LL-37 also inhibits adhesion of *C. albicans* to plastics and tissues by interacting with yeast cell wall carbohydrates ([@B250]). When the peptide LL-37 was tested for their inhibitory effects and antibiofilm properties against *C. albicans* strain, using both a crystal violet and an XTT \[2,3-bis- (2-methoxy-4-nitro-5-sulfophenyl) -2H -tetrazolium-5-carboxanilide\] assays showed satisfactory results, mainly in relation to the prevention of biofilms. Through violet crystal analysis, LL-37 had significant efficacy both in preventing biofilm formation and in inhibiting early formed biofilms of *C. albicans*. However, by XTT metabolic assay, LL-37 prevented biofilm formation against *C. albicans*, even at sub-minimum inhibitory concentrations (sub-MIC), but did not inhibit early biofilms ([@B123]).

Although natural proteins/peptides represent a promising therapeutic agents, they are usually extracted in small amount which makes it difficult to perform biological tests ([@B20]). Stimulated by these facts, some researchers are synthetizing or modifying existing natural peptides in order to obtaining new molecules with enhanced antifungal activity and reduced toxicity. For instance, a shortened peptide variant of CRAMP, named P318 (**Table [3](#T3){ref-type="table"}**), was identified by [@B23] and shared 67% identity with the peptide LL-37. The peptide was discovered in the islets of Langerhans of the murine pancreas. P318 showed biofilm-specific activity as it inhibited *C. albicans* biofilm formation at 0.15 μM without affecting planktonic survival at that concentration.

[@B141] synthesized and characterized nine new cationic peptides, rich in arginine and lysine amino acids to introduce cationic charges and in phenylalanine and leucine residues to increase lipophilicity. Four from these peptides showed a potente antifungal activity against different clinical isolates of *Candida* spp. (MIC ranged from 62.5 to 500 μg).

[@B43] delineated and identified a linear HsLin06_18, a 19-mer peptide (**Table [3](#T3){ref-type="table"}**) derived from the C-terminal part of HsAFP1, an antifungal and antibiofilm plant defensin isolated from *Heuchera sanguinea*. Synergistic combination of HsLin06_18 with caspofungin significantly reduced *in vitro* biofilm formation of *C. glabrata* and *C. albicans* on catheters, as well as *in vivo* biofilm formation of *C. albicans* strain. In addition, combination dose (4.6 μM of HsLin06_18 + 0.01 μM caspofungin) was fungicidal against planktonic cells of tested strains, killing until 80% of yeast population. [@B116] demonstrated the antifungal and antibiofilm activities of a synthetic peptide consisting of 15 amino acids at the C-terminus of human β-defensin 3 (HBD3-C15, **Table [3](#T3){ref-type="table"}**). They observed that the biofilm of *C. albicans* on dentin disks was inhibited by HBD3-C15 in a dose-dependent manner.

Despite promises, much research is still needed on hemolytic activity, instability, production modes, interaction with high salt concentrations, anti-virulence activity, and poor ability to cross physiological barriers of these peptides, which could limit their use in the clinic.

Plants as a Source for Anti-*Candida* Natural Compounds
-------------------------------------------------------

The use of plants and their bioactive molecules in the treatment of candidiasis has emerged as a promising alternative to traditional drugs against resistance which has developed in the *Candida* genus. Antifungal substances derived from plants can selectively act on different targets with fewer side effects. In addition, the practice of phytotherapy is inexpensive; therefore, floral diversity has resulted in an increase in potential usage in populations experiencing economic difficulties. This review comments on some of the extracts of plants or their metabolites that *in vitro* and *in vivo* studies have already demonstrated a potential antifungal activity.

There are some families of plants that are more studied than others as the *Combretaceae* and *Acanthaceae*. Studies have shown that leaves, seeds, fruits, and flowers have the most enriched plant components. Leaves, as well as the seeds and fruits of plants have higher levels of phenolic compounds. The concentration of these compounds also depends on the nature of the chemical used as solvent in the extraction process as well as on the growth and storage conditions ([@B129]). The most used solvents in extraction processes are dichloromethane, methanol, ethanol, ethyl acetate and n-butanol. ([@B129]).

Recently, some authors have verified and evaluated the biological activity of plant products against *Candida* species. *Lonicera japonica*, a medicinal plant of folk medicine of China used to treat some diseases, was investigated by [@B40] for the *in vivo* activity of an ethanol extract of its aerial parts. The extract showed a very strong antimicrobial activity against *C. albicans* and *C. tropicalis* and potent wound healing capacity; further, enhanced production of anti-inflammatory cytokines was observed. In this way, the authors suggested that both activities detected in this extracts act synergistically accelerating the process of wound healing.

Some properties of *Lannea welwitschii* and *Justicia flava* were investigated by [@B2]. Methanolic extract of *Lannea welwitschii* leaves was antimicrobial against clinical strains of *C. albicans* and other microorganisms. The MIC for *C. albicans* was 2.5 mg/mL. Treatment with an extract from both plants resulted in a significant decrease in wound size and increase in wound tensile strength. A preliminary phytochemical screening of extracts revealed tannins, flavonoids, alkaloids, and glycosides as compounds. These results corroborate the use of these vegetable extracts in treatment of wounds and infections in phytotherapy.

[@B174] studied the activity of *Pyrostegia venusta* crude flower extracts, fractions, and pure compounds against isolates of *Candida* spp. and showed an effective broad spectrum antifungal activity. [@B159] reported anticandidal activity in an extract of *Piper betle* leaves; in fact, the extract inhibited the growth of all *Candida* species tested. [@B95] also verified antimicrobial property of four different extracts of *Strychnos spinosa* and their fractions against American Type Culture Collection (ATCC) strains of *C. albicans* and *C. albicans* isolates (MICs of 0.16 and 0.63 mg/mL, respectively). [@B162] described that silver nanoparticles containing *Manilkara zapota* seed extracts showed good activity against *Candida* species.

[@B224] evaluated the antifungal potential of 14 polyphenols against various *C. albicans* clinical isolates in terms of planktonic and sessile MICs (PMICs and SMICs, respectively). Among these, 7 were able to inhibit planktonic growth. The most effective was pyrogallol (PMIC~50~ = 78 μg/mL) and curcumin (PMIC~50~ = 100 μg/mL). In addition, curcumin inhibited adhesion capability of cells and demonstrated anti-biofilm activity against *C. albicans* (SMIC~50~ = 50 μg/mL).

[@B130] evaluated ten different plant extracts commonly used in folk medicine for antifungal activity against *Candida* spp. They verified that hydro-methanolic extracts of leaves from two of these plants, *Juglans regia* and *Eucalyptus globulus*, demonstrated excellent antimycotic property against all *Candida* strains. [@B77] described anticandidal activity in a *Cynomorium coccineum* methanol extract, which showed excellent action against *C. guilliermondii* and *C. krusei*, showing very low MIC values (0.025 mg/mL). [@B143] investigated the antimycotic property of a hydroethanolic extract of *Uncaria tomentosa* and some of its fractions against resistant *Candida* spp. and verified that the water-insoluble fraction showed significant antifungal activity.

[@B3] showed antifungal activity in an acetylic extract of *Vicia faba* against *C. albicans* (MIC of 0.010 mg/mL) *in vitro*. Further, mortality rates were reduced in mice that were administered with the extract (20 μg/mL) for treatment of candidiasis.

[@B45] evaluated the antifungal properties of six plants from Brazilian Cerrado commonly used in folk medicine (ethanolic and aqueous extracts) against different *Candida* reference strains using the disk diffusion method and determining MICs. Among these plants, the most promising were *Eugenia dysenterica* and *Pouteria ramiflora.* They showed excellent activity against *C. tropicalis*, *C. famata*, *C. krusei*, *C. guilliermondii*, and *C. parapsilosis* with low MICs values. A phytochemical screening of active extracts from these plants disclosed as main components flavonoids and catechins.

[@B243] found antifungal properties in crude extract and fractions (n-butanolic and ethyl acetate ones) from *Terminalia catappa* leaves via the agar diffusion and microdilution tests when analyzed against *Candida* spp.; hydrolysable tannins (punicalin, punicalagin), gallic acid, and flavonoid *C*-glycosides are likely the active components. [@B245] verified the antifungal activity of polyphenols (flavanol monomers such as epicatechin and catechin, and procyanidin oligomers) of alkalized/non-alkalized *Theobroma cacao* powders against *C. albicans* (ATCC 10231) and determined a MIC value of 5.0 mg/mL using the broth microdilution method.

Phytochemicals present in leaves of *Carya illinoensis* were first identified by [@B21], and the antimicrobial activity of their aqueous and ethanolic extracts was determined. Both extracts had MIC values against seven *Candida* reference strains between 25 mg/mL and 6.25 mg/mL. Phenolic acids (gallic acid and ellagic acid), flavonoids (rutin), and tannins (catechins and epicatechins) were likely responsible, in part, for the activity against *Candida* strains. Further, the extracts inhibited the production of *C. albicans* germ tubes.

Important biologically active molecules are found in plants ([@B131]). Polyphenols are a kind of substance most found in plants; they are low molecular weight naturally occurring organic compounds that contain one or more phenolic groups ([@B52]; [@B224]). Further, polyphenols perform various substantial functions in plant physiology and, therefore, can be found, in lesser or greater quantity, in all of them. Phenolic acids, flavonoids, tannins, coumarins, are some examples of phenolic compounds found in and extracted from medicinal plants ([@B52]). Research has shown that polyphenols have potentially healthy effects in humans, working primarily as anticancer, antihypertensive, anti-allergen, anti-inflammatory, antioxidants, and antimicrobial agents. The antimicrobial activity of polyphenols has been extensively investigated mainly against bacteria ([@B52]).

Nevertheless, the antifungal activity of some of the above-mentioned phenolic compounds remains unknown and determining the antifungal activity of such compounds remains an open area of research. Reports of studies of phenolic compounds against *Candida* are still scarce. There are few studies on the mechanism of action of the substance, cytotoxicity, the synergism with traditional antifungals drugs and their anti-virulence activities (such as inhibition of biofilm formation, interference of adhesion capability, interference of hyphal formation or inhibition of exoenzymes production).

Flavan-3-ols, flavonols, and tannins have received the most attention among the known polyphenols, attributable to their large spectrum of efficacy and high antimicrobial property, which have been shown in many bacteria strains and isolates. Further, virulence factors of bacteria may be influenced by polyphenols and also these substances can act in synergism with antibiotics; consequently, those polyphenols are also the most studied in relation to their anti-*Candida* activities. Thus, we reviewed the antifungal activities related in scientific literature of the polyphenols considered most actives and their mechanisms of action.

Flavonoids are a class of natural compounds with several known protective activities, including antifungal activity. The flavonoids include subclasses such as chalcones, flavones, isoflavones, flavonols, flavanols (flavan-3-ol), and anthocyanidins ([@B217]). The activity of flavonols such as quercetin, myricetin, and kaempferol has been described in *C. albicans*. [@B90] showed inhibition of *C. albicans* growth with isolated flavonols from propolis using quercetin in an agar microdilution method, obtained a variation of MIC values from 197 to 441 μg/mL. These same authors found similar results for myricetin and kaempferol against *Candida* species ([@B90]). Other studies have reported antimicrobial activity ([@B10]; [@B16]) for other propolis polyphenols such as flavanone (pinocembrin and pinostrobin) and chalcones (2,4-dihydroxychalcone and 2,4-dihydroxy-3-methoxychalcone). The flavanols subclass (flavan-3-ol) and gallotannin, extracted from *Syzygium cordatum*, also showed inhibitory properties on the growth of *C. albicans*, with a MIC of 0.195 mg/mL in a microdilution test ([@B152]). [@B221] isolated baicalein, belonging to a subclass of flavones, from *Scutellaria baicalensis*, and induced apoptosis in *C. albicans*, with a MIC value of 26 μg/mL. Apigenin, a flavone isolated from propolis, had a MIC of 441 μg/mL against *C. albicans*, as shown using a microdilution test.

Tannins are polyphenolic compounds present in various plant parts, such as the roots, flowers, leaves, fruits, and seeds. Tannins are divided into ellagitannins (hydrolysable tannins), proanthocyanidins (condensed tannins) and gallotannins ([@B61]). They have the ability to interact with and precipitate macromolecules such as proteins ([@B59]), as well as having antimicrobial properties. However, the mechanisms underlying the antimicrobial action of tannins in different microorganisms such as bacteria and fungi are still under investigation ([@B146]; [@B267]; [@B59]).

The knowledge that wood durability could be attributed to the accumulation of ellagitannins, with the ability to precipitate proteins and/or withdraw metallic cofactors acting as a microbial barrier, raised the suspicion that ellagitannins would have antifungal activity. Accordingly, ellagitannins isolated from *Ocotea odorifera*, a plant commonly used in Brazil in folk medicine, have a very good activity against *C. parapsilosis* ([@B268]). [@B59] verified that encapsulated tannins from *Acacia mearnsii* have moderate activity against the filamentous fungi *Aspergillus niger* (ATCC 9642) and *C. albicans* (ATCC 34147).

Other phytosubstances reported to be active against yeasts and fungi include essential oils, which are derived from aromatic medicinal plants ([@B195]; [@B223]; [@B30]; [@B253]; [@B186]; [@B232]). Essential oils are rich in monoterpenes, sesquiterpenes, and/or phenylpropanoids, considerate volatile organic compounds. Essential oils are present in various plant species. [@B142] proposed that tea tree oil could be used in antifungal therapy, because it showed efficacy against multidrug-resistant *Candida* species *in vitro* and against mucosal candidiasis *in vivo*; they further documented that terpinen-4-ol was the main substance to contribute to the anticandidal activity.

Several oils have demonstrated activity against *Candida* species. Essential oils from *Carica papaya* have inhibitory effects against *Candida* species, as shown via the agar diffusion method and the microdilution method, with MICs between 4 and 16 mg/mL and MFCs between 16 and 64 μg/mL ([@B227]; [@B228]; [@B89]). [@B138] tested a combination of essential oils from *Cuminum cyminum* and *Lavandula binaludensis* against *C. albicans* isolates, showing growth inhibition at concentrations between 3.90 and 11.71 μg/mL. Essential oils from *Cymbopogon nardus* have also shown antimicrobial potential against *Candida* species, with MICs between 250 and 1000 μg/mL and with inhibition of hyphal growth in *C. albicans* at concentrations between 15.8 and 1000 μg/mL ([@B56]). In addition to inhibiting biofilm formation ([@B1]), essential oils from *Artemisia judaica* have been shown to inhibit the formation of germination tubes in *C. albicans*, with 80% inhibition of filamentation at a concentration of 0.16 μL/mL. [@B106] demonstrated the fungicidal potential of essential oils from *Centaurea baseri* against *Candida* species, with a MIC of 60 μg/mL.

[@B226] observed that essential oils from *Trachyspermum ammi* have anticandidal effects against isolates of *C. albicans*, some of which were resistant to FLZ. [@B73] have compared the efficiency of herbal essences from *Foeniculum vulgare, Satureja hortensis, C. cyminum*, and *Zataria multiflora* against *C. albicans.* Essential oils from *Z. multiflora* showed the best anticandidal activity of those tested, with MIC and MFC values of 34 and 64 μg/mL, respectively.

Among monoterpenes there is thymol (2-isopropyl-5-methylphenol), ([@B203]). It is the most abundant constituent in essential oils from *Thymus vulgaris* (thyme) ([@B55]) and the major component of essential oils from *Origanum vulgare* (oregano) ([@B199]). Antifungal activity of thymol was investigated by [@B54] against *Candida* strains. They verified fungistatic and fungicidal activity, mechanisms of action and mode of interactions in combination with nystatin. Thymol had antifungal properties, with MIC of 39 μg/mL against *C. albicans* and *C. krusei*, and MIC of 78 μg/mL against *C. tropicalis*. Antifungal assays also showed an eightfold increase (from 39.0 to 312.5 μg/mL) in thymol MIC values against *C. albicans* in the presence of exogenous ergosterol, indicating that thymol binds to ergosterol in the plasma membrane, thereby increasing ion permeability and resulting in cell death. Combination of thymol and nystatin resulted in synergy.

Terpenoids exhibit a very good antimycotic activity against blastopores and filamentous forms growth of *C. albicans* at concentrations that are non-toxic to HeLa cells ([@B271]). Accordingly, terpenoids may be useful as a future antifungal chemotherapeutic agent, in addition to its synergistic effects with conventional drugs such as FLZ ([@B271]). Further, in experiments realized by [@B65], rubiarbonol G, a triterpenoid from *Rubia yunnanensis*, showed potent antimicrobial activity against *C. albicans*, with a MIC of 10.5 μg/mL.

The anti-biofilm activity of terpenes, along with the efficacy of thymol, geraniol, and carvacrol in the treatment of *Candida* infections associated with the use of hospital devices has been related ([@B53]). Mechanisms underlying the effects associated with carvacrol include alterations of the cellular cytoplasmic membrane and induction of apoptosis, as shown in an *in vitro* macrodilution study in *Candida* species ([@B152]).

Phenylpropanoids are other naturally occurring compounds frequently studied for their anti-*Candida* properties; they are categorized as coumarins, phenylpropanoic acid, and lignans ([@B122]). [@B153] and [@B192], found that a coumarin (scopoletin) and two phenylpropanoic acids (salicylaldehyde and anisyl alcohol) have antifungal property against *C. albicans*, with MICs of 25, 31, and 31 μg/mL, respectively.

Taken together these data show that plants contain molecules possessing high bioactive potential. However, the process of discovering bioactive molecules is complex and time-consuming, involving the isolation, identification, and optimization of pharmacokinetic and pharmacodynamic properties, as well as the selection of lead compounds for further drug development.

Synergistic Effects of Plant Extracts or Their Phytoconstituents With Traditional Agents
----------------------------------------------------------------------------------------

The knowledge about synergistic effects of plant extracts or their phytoconstituents with traditional agents is nowadays a type of study that is indispensable, since some screening assays, most realized *in vitro*, have evidenced that plant extracts are less effective than existing antifungal agents ([@B155]) and that extracts with MIC of 1000 μg/mL are considered inefficient ([@B144]).

The use of drug combinations in treatment of infections by fungi is a preferred strategy clinically. Although combination of medications requires a careful evaluation of the synergistic, antagonistic, and agonist properties of the drugs involved ([@B113]), it has been used successfully in many cases of fungal infection ([@B220]; [@B64]; [@B19]; [@B198]) (**Table [1](#T1){ref-type="table"}**). The synergistic effects of drugs are primarily attributable to cell wall damage as one antifungal component potentiates the activity of drugs exactly against some constituent of plasma membrane. Alternatively, a compromised cell wall has increased permeability and could facilitate movement of drugs across the cell membrane to their targets.

Accordingly, the synergistic effect of plant extracts or their biomolecules in combination with conventional antimicrobial agents (or with some other different extract or biosubstance) against clinical multidrug-resistant microorganisms represents a successful therapeutic approach ([@B151]). Advantages of combination therapies include lower doses of antifungal agent, possible synergistic actions between antifungals, and less development of drug resistance. The objective of this strategy is to maximize the antifungal effects. Some examples are addressed herein.

[@B242] reported synergy between essential oils or plant extracts associated with antifungal drugs when used as anti-*C. albicans* agents. The best synergistic effects were obtained for combination between itraconazole and *P. bredemeyeri* extract \[fractional inhibitory concentration index (FICI) range of 0.09--0.13\] against *C. albicans.*

[@B33] verified a synergistic potential when methanolic extract of *T. catappa* leaves was combined with nystatin or AMB against *C. albicans* (ATCC 209), *C. neoformans* (National Collection of Industrial Microorganisms \[NCIM\] 3542), *C. glabrata* (NCIM 3448), *C. apicola* (NCIM 3367), and *Trichosporon beigelii* (NCIM 3404). As such, maximum synergy was observed against *C. apicola*.

[@B212] related the antimycotic properties of an ethanol extract of *Hyptis martiusii* (EEHM) against *C. albicans, C. krusei*, and *C. tropicalis.* They verified synergistic antifungal activity for EEHM in combination with metronidazole when used against *C. tropicalis*.

[@B9] reported a synergistic effect between an *Echinophora platyloba* ethanolic extract and different azoles against isolates of *C. albicans* from vaginal secretions of patients with recurrent vulvovaginitis. MIC and MFC values ranged from 3.1 to 6.25 mg/mL and 6.2 to 12.5 mg/mL, respectively, showing potent synergistic effects of the *E. platyloba* ethanol extract in combination with itraconazole and FLZ.

Combination between thymol and nystatin was found to have synergistic effects against *Candida* species ([@B54]), reducing the MICs of both products by 87.4% and generating a fractional inhibitory concentration (FIC) index of 0.25.

Synergism between a water insoluble fraction (WIF) from *U. tomentosa* (cat's claw) bark and the agents terbinafine or FLZ was investigated against seven resistant isolates of *C. glabrata* and *C. krusei* via the checkerboard procedure using a microdilution technique ([@B143]). Synergism was observed between the *U. tomentosa* WIF and terbinafine, as well as between the *U. tomentosa* WIF and FLZ. The most efficacious synergistic effects leading to cell damage were unequivocally attributed to a combination of the *U. tomentosa* WIF and terbinafine (1.95:4.0, l g/mL), as well as the *U. tomentosa* WIF and FLZ (1.95:8.0, l g/mL). [@B143] also demonstrated, through differential scanning calorimetry and infrared analysis, that intermolecular interactions between the *U. tomentosa* WIF components and either terbinafine or FLZ occurring outside the cell wall are likely responsible for synergistic effects observed between substance. An action on constituents of the cell wall was suggested, independent of ABC efflux pump mechanisms.

[@B156] conducted a bioguided screening with sub-fraction combinations of *T. catappa, Terminalia mantaly*, and *Monodora tenuifolia* against *C. albicans*, *C. glabrata*, *C. parapsilosis*, and *C. neoformans* isolates, as well as the *C. albicans* NR-29450 reference strain. They observed synergistic interactions between subfractions combinations. A combination of *M. tenuifolia* and *T. mantaly* (C36/C12) sub-fractions showed synergistic interactions and fungicidal effects against most tested strains.

[@B29] verified that the methanolic extract of *Buchenavia tetraphylla* is a great source of antimicrobial compounds that enhance the action of FLZ against different *C. albicans* isolates from vaginal secretions as well as azole-resistant isolates. The extract increased the action of FLZ in most strains through additive (20% of strains) or synergistic (60% of strains) effects.

Although many *in vitro* studies examining synergistic effects among potential antifungal biomolecules and traditional antifungal agents have been reported in the literature as described herein, the mechanisms underlying these synergistic effects are poorly understood. Several randomized and controlled analyzes have been performed with the objective of verifying the efficacy and risks of using traditional antifungal combinations; however, the high cost, reduced number of clinical cases and existence of confusing variables have resulted in contradictory and poor results. Therefore, it is extremely relevant the constant search for new phytocompounds to examine carefully possible synergism between them and conventional antifungal agents in order to obtain more insight. A lack of consensus in the medical clinical emphasizes the need to conduct further clinical trials using combinations of antifungals. The experiments and results addressed herein support further investigation of new plant constituents with antifungal properties and the efficacy of combination therapies involving phytocomponents and traditional antifungal agents as an important start for the development of unusual and original antifungal therapies.

Concluding Remarks
==================

*Candida* species are highly resistant to existing antifungal agents and can adapt to different host niches thus representing a serious risk to human health. The mechanisms underlying development of antifungal resistance are complex and involve multiple pathways and genes. Further, these mechanisms continue to change and evolve, challenging the medical clinic and exacerbating the need for discovering original therapies against *Candida* diseases. In this way, identification of new bioactive compounds as well as development of original formulations of antifungals and combinations involving active biomolecules and conventional agents represents the possibility for a successful therapeutic approach.
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